Who are Ztalmy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zurzuvae, Zulresso, ZULRESSO®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ganaxolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ztalmy — Competitive Intelligence Brief

Ztalmy (GANAXOLONE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]. Area: Neuroscience.

marketed Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] GABA A receptor alpha-2/beta-1/gamma-2 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Ztalmy (GANAXOLONE) — Marinus. Ztalmy works by enhancing the activity of the GABA A receptor, a key player in regulating the activity of neurons in the brain.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ztalmy TARGET	GANAXOLONE	Marinus	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-2/beta-1/gamma-2	2022-01-01
Zurzuvae	ZURANOLONE	Biogen	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-4/beta-3/delta	2023-01-01
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
ZULRESSO®	ZULRESSO®	Supernus Pharmaceuticals, Inc.	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] class)

Biogen · 1 drug in this class
Marinus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ztalmy — Competitive Intelligence Brief. https://druglandscape.com/ci/ganaxolone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab